vs
Embecta Corp.（EMBC）与Purple Innovation, Inc.（PRPL）财务数据对比。点击上方公司名可切换其他公司
Embecta Corp.的季度营收约是Purple Innovation, Inc.的1.9倍（$261.2M vs $140.7M），Embecta Corp.净利率更高（16.9% vs -2.3%，领先19.2%），Purple Innovation, Inc.同比增速更快（9.1% vs -0.3%），Embecta Corp.自由现金流更多（$16.6M vs $-7.8M），过去两年Purple Innovation, Inc.的营收复合增速更高（8.3% vs -4.6%）
Embecta Corp.是一家专注于糖尿病护理领域的全球医疗科技企业，主要设计、生产及销售胰岛素笔针、注射器、输注组件等给药装置，产品服务覆盖全球多个地区的患者、医疗机构及生物制药合作方。
Purple Carrot是一家总部位于马萨诸塞州尼达姆市的全植物性餐包品牌，由安迪·莱维特创立，每周为订阅用户提供预制餐品和自制餐包。据《大都会》2022年报道，对比美式标准餐食，该品牌每份餐包的碳排放量可降低72%，主打低碳环保的纯植物饮食方案。
EMBC vs PRPL — 直观对比
营收规模更大
EMBC
是对方的1.9倍
$140.7M
营收增速更快
PRPL
高出9.3%
-0.3%
净利率更高
EMBC
高出19.2%
-2.3%
自由现金流更多
EMBC
多$24.4M
$-7.8M
两年增速更快
PRPL
近两年复合增速
-4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $261.2M | $140.7M |
| 净利润 | $44.1M | $-3.2M |
| 毛利率 | 61.9% | 41.9% |
| 营业利润率 | 31.9% | -1.6% |
| 净利率 | 16.9% | -2.3% |
| 营收同比 | -0.3% | 9.1% |
| 净利润同比 | — | 62.1% |
| 每股收益（稀释后） | $0.74 | $0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMBCPRPL
| Q4 25 | $261.2M | $140.7M | ||
| Q3 25 | $264.0M | $118.8M | ||
| Q2 25 | $295.5M | $105.1M | ||
| Q1 25 | $259.0M | $104.2M | ||
| Q4 24 | $261.9M | $129.0M | ||
| Q3 24 | $286.1M | $118.6M | ||
| Q2 24 | $272.5M | $120.3M | ||
| Q1 24 | $287.2M | $120.0M |
净利润EMBCPRPL
| Q4 25 | $44.1M | $-3.2M | ||
| Q3 25 | $26.4M | $-11.7M | ||
| Q2 25 | $45.5M | $-17.3M | ||
| Q1 25 | $23.5M | $-19.1M | ||
| Q4 24 | $0 | $-8.5M | ||
| Q3 24 | $14.6M | $-39.2M | ||
| Q2 24 | $14.7M | $27.0K | ||
| Q1 24 | $28.9M | $-50.2M |
毛利率EMBCPRPL
| Q4 25 | 61.9% | 41.9% | ||
| Q3 25 | 60.0% | 42.8% | ||
| Q2 25 | 66.7% | 35.9% | ||
| Q1 25 | 63.4% | 39.4% | ||
| Q4 24 | 60.0% | 42.9% | ||
| Q3 24 | 60.7% | 29.7% | ||
| Q2 24 | 69.8% | 40.7% | ||
| Q1 24 | 64.6% | 34.8% |
营业利润率EMBCPRPL
| Q4 25 | 31.9% | -1.6% | ||
| Q3 25 | 21.4% | -10.2% | ||
| Q2 25 | 31.8% | -13.5% | ||
| Q1 25 | 24.3% | -13.9% | ||
| Q4 24 | 11.0% | -6.0% | ||
| Q3 24 | 9.2% | -39.5% | ||
| Q2 24 | 20.5% | -12.1% | ||
| Q1 24 | 13.6% | -19.3% |
净利率EMBCPRPL
| Q4 25 | 16.9% | -2.3% | ||
| Q3 25 | 10.0% | -9.9% | ||
| Q2 25 | 15.4% | -16.5% | ||
| Q1 25 | 9.1% | -18.4% | ||
| Q4 24 | — | -6.6% | ||
| Q3 24 | 5.1% | -33.1% | ||
| Q2 24 | 5.4% | 0.0% | ||
| Q1 24 | 10.1% | -41.8% |
每股收益（稀释后）EMBCPRPL
| Q4 25 | $0.74 | $0.03 | ||
| Q3 25 | $0.44 | $0.11 | ||
| Q2 25 | $0.78 | $0.16 | ||
| Q1 25 | $0.40 | $0.18 | ||
| Q4 24 | $0.00 | $0.08 | ||
| Q3 24 | $0.24 | $0.36 | ||
| Q2 24 | $0.25 | $0.00 | ||
| Q1 24 | $0.50 | $0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.3M | $24.3M |
| 总债务越低越好 | — | $126.7M |
| 股东权益账面价值 | $-613.1M | $-29.7M |
| 总资产 | $1.1B | $296.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EMBCPRPL
| Q4 25 | $201.3M | $24.3M | ||
| Q3 25 | $225.5M | $32.4M | ||
| Q2 25 | $230.6M | $34.2M | ||
| Q1 25 | $209.3M | $21.6M | ||
| Q4 24 | $210.0M | $29.0M | ||
| Q3 24 | $267.5M | $23.4M | ||
| Q2 24 | $275.1M | $23.4M | ||
| Q1 24 | $299.8M | $34.5M |
总债务EMBCPRPL
| Q4 25 | — | $126.7M | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $70.7M | ||
| Q3 24 | $1.6B | $50.8M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EMBCPRPL
| Q4 25 | $-613.1M | $-29.7M | ||
| Q3 25 | $-650.6M | $-26.9M | ||
| Q2 25 | $-669.6M | $-15.6M | ||
| Q1 25 | $-736.2M | $1.3M | ||
| Q4 24 | $-768.8M | $20.2M | ||
| Q3 24 | $-738.3M | $28.0M | ||
| Q2 24 | $-763.7M | $66.4M | ||
| Q1 24 | $-769.6M | $65.5M |
总资产EMBCPRPL
| Q4 25 | $1.1B | $296.3M | ||
| Q3 25 | $1.1B | $302.1M | ||
| Q2 25 | $1.2B | $303.8M | ||
| Q1 25 | $1.1B | $293.8M | ||
| Q4 24 | $1.1B | $307.8M | ||
| Q3 24 | $1.3B | $309.3M | ||
| Q2 24 | $1.3B | $362.1M | ||
| Q1 24 | $1.2B | $382.1M |
负债/权益比EMBCPRPL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.50× | ||
| Q3 24 | — | 1.82× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.2M | $-5.8M |
| 自由现金流经营现金流 - 资本支出 | $16.6M | $-7.8M |
| 自由现金流率自由现金流/营收 | 6.4% | -5.5% |
| 资本支出强度资本支出/营收 | 0.2% | 1.4% |
| 现金转化率经营现金流/净利润 | 0.39× | — |
| 过去12个月自由现金流最近4个季度 | $205.8M | $-41.9M |
8季度趋势，按日历期对齐
经营现金流EMBCPRPL
| Q4 25 | $17.2M | $-5.8M | ||
| Q3 25 | $84.0M | $-968.0K | ||
| Q2 25 | $81.2M | $-4.0M | ||
| Q1 25 | $31.8M | $-23.1M | ||
| Q4 24 | $-5.3M | $6.8M | ||
| Q3 24 | $26.6M | $1.1M | ||
| Q2 24 | $-2.1M | $-8.9M | ||
| Q1 24 | $24.3M | $-16.8M |
自由现金流EMBCPRPL
| Q4 25 | $16.6M | $-7.8M | ||
| Q3 25 | $76.7M | $-1.8M | ||
| Q2 25 | $80.8M | $-7.0M | ||
| Q1 25 | $31.7M | $-25.3M | ||
| Q4 24 | $-6.8M | $5.7M | ||
| Q3 24 | — | $101.0K | ||
| Q2 24 | $-11.8M | $-11.0M | ||
| Q1 24 | $20.9M | $-19.9M |
自由现金流率EMBCPRPL
| Q4 25 | 6.4% | -5.5% | ||
| Q3 25 | 29.1% | -1.5% | ||
| Q2 25 | 27.3% | -6.6% | ||
| Q1 25 | 12.2% | -24.3% | ||
| Q4 24 | -2.6% | 4.4% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | -4.3% | -9.2% | ||
| Q1 24 | 7.3% | -16.5% |
资本支出强度EMBCPRPL
| Q4 25 | 0.2% | 1.4% | ||
| Q3 25 | 2.8% | 0.7% | ||
| Q2 25 | 0.1% | 2.8% | ||
| Q1 25 | 0.0% | 2.2% | ||
| Q4 24 | 0.6% | 0.8% | ||
| Q3 24 | 0.0% | 0.9% | ||
| Q2 24 | 3.6% | 1.7% | ||
| Q1 24 | 1.2% | 2.5% |
现金转化率EMBCPRPL
| Q4 25 | 0.39× | — | ||
| Q3 25 | 3.18× | — | ||
| Q2 25 | 1.78× | — | ||
| Q1 25 | 1.35× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.82× | — | ||
| Q2 24 | -0.14× | -330.22× | ||
| Q1 24 | 0.84× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
PRPL
| Cost Of Revenues | $81.7M | 58% |
| Other | $59.0M | 42% |
